TARGET-SCD Innovating Sickle Cell Disease Treatment: From Non-Canonical Signaling and Immune Activation to Personalized Targeted Therapies
- Coordinator
- Universite Paris Cite, France
- Runs
- 1 January 2027 to 31 December 2031
- Status
- Running
- EU funding
- €2.4m
- Total cost
- —
- Partners
- 2 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101268370
What the project is doing
In the project's own words, from its summary on CORDIS.
This project addresses the unmet clinical needs of sickle cell disease (SCD), the most common monogenic disorder worldwide, characterized by chronic inflammation, multi-organ involvement, and severely impaired erythropoiesis. SCD pathophysiology is driven by hemoglobin S polymerization, leading to vaso-occlusion (VOC) and acute chest syndrome (ACS), oxidative stress, and activation of innate immunity. Our multidisciplinary approach combines patient-driven biomarker studies, mechanistic investigations in human and mouse models, and exploration of innovative therapies.
Preliminary data reveal that chronic bone marrow inflammation impairs hematopoietic stem/progenitor cell functions, alters erythroid differentiation, and increases myeloid bias, all contributing to poor transplant and gene therapy outcomes. Novel research in our group highlights the role of non-canonical histidine phosphorylation (NME1/NME2) in regulating BCL11A activity for fetal hemoglobin synthesis, and demonstrates that pharmacological targeting of these kinases safely induces HbF in human progenitors.
We also uncover critical roles for mast cells and basophils, showing that their activation drives pain, vaso-occlusion, and neuroinflammation. Candidate drugs, including masitinib, luspatercept, and anti-inflammatory agents, are tested for their ability to improve hematopoiesis, reduce acute and chronic complications, and modulate the bone marrow niche. By integrating high-throughput sequencing, multi-omic profiling, and advanced mouse genetics, this project aims to identify new biomarkers and therapeutic strategies to personalize SCD care, improve gene therapy success, and rapidly translate findings from bench to bedside, offering hope for patients globally.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universite Paris Cite | Paris | France | Coordinator |
| Imagine Institut Des Maladies Genetiques Necker Enfants Malades Fondation | Paris | France | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI